BeiGene Ltd (BGNE)
194.56
+0.30
(+0.15%)
USD |
NASDAQ |
Nov 21, 16:00
194.76
+0.20
(+0.10%)
After-Hours: 20:00
BeiGene Enterprise Value: 19.09B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 19.09B |
| November 20, 2024 | 19.06B |
| November 19, 2024 | 18.37B |
| November 18, 2024 | 18.36B |
| November 15, 2024 | 18.52B |
| November 14, 2024 | 18.96B |
| November 13, 2024 | 19.19B |
| November 12, 2024 | 18.99B |
| November 11, 2024 | 20.21B |
| November 08, 2024 | 20.26B |
| November 07, 2024 | 20.40B |
| November 06, 2024 | 19.96B |
| November 05, 2024 | 20.53B |
| November 04, 2024 | 20.45B |
| November 01, 2024 | 20.12B |
| October 31, 2024 | 19.88B |
| October 30, 2024 | 20.23B |
| October 29, 2024 | 21.34B |
| October 28, 2024 | 21.42B |
| October 25, 2024 | 20.95B |
| October 24, 2024 | 21.09B |
| October 23, 2024 | 21.82B |
| October 22, 2024 | 21.78B |
| October 21, 2024 | 21.70B |
| October 18, 2024 | 21.60B |
| Date | Value |
|---|---|
| October 17, 2024 | 20.90B |
| October 16, 2024 | 21.94B |
| October 15, 2024 | 21.99B |
| October 14, 2024 | 22.46B |
| October 11, 2024 | 23.42B |
| October 10, 2024 | 23.77B |
| October 09, 2024 | 23.88B |
| October 08, 2024 | 23.35B |
| October 07, 2024 | 24.16B |
| October 04, 2024 | 24.48B |
| October 03, 2024 | 23.16B |
| October 02, 2024 | 23.16B |
| October 01, 2024 | 22.88B |
| September 30, 2024 | 22.19B |
| September 27, 2024 | 21.61B |
| September 26, 2024 | 20.99B |
| September 25, 2024 | 20.37B |
| September 24, 2024 | 20.65B |
| September 23, 2024 | 19.80B |
| September 20, 2024 | 19.87B |
| September 19, 2024 | 19.51B |
| September 18, 2024 | 19.37B |
| September 17, 2024 | 19.40B |
| September 16, 2024 | 19.28B |
| September 13, 2024 | 19.50B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
6.437B
Minimum
Mar 31 2020
33.75B
Maximum
Sep 17 2021
18.22B
Average
17.49B
Median
Aug 18 2023
Enterprise Value Benchmarks
| Theravance Biopharma Inc | 381.20M |
| Merck & Co Inc | 276.21B |
| Bristol-Myers Squibb Co | 159.82B |
| Zai Lab Ltd | 2.259B |
| Halozyme Therapeutics Inc | 6.652B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -121.35M |
| Revenue (Quarterly) | 1.002B |
| Total Expenses (Quarterly) | 1.122B |
| EPS Diluted (Quarterly) | -1.17 |
| Gross Profit Margin (Quarterly) | 82.98% |
| Profit Margin (Quarterly) | -12.12% |
| Earnings Yield | -4.28% |
| Normalized Earnings Yield | -4.276 |